The prognostic and predictive role of KRAS mutations in advanced nonsmall-cell lung cancer (NSCLC) is still unclear. TAILOR prospectively assessed the prognostic and predictive value of KRAS mutations in NSCLC patients treated with erlotinib or docetaxel in second line.
meta-analyses supported KRAS as negative predictor for EGFR tyrosine kinase inhibitors (TKI) treatment but only in regards of RR [7, 8] . It has been suggested that the inconsistency of these contradictory findings might reflect prognostic and predictive differences within the range of KRAS mutations [9, 10] , adding to the inherent biases due to the high percentage of patients with unknown KRAS status, in most cases as high as 80% [11] , due in turn to the retrospective and unplanned nature of the analyses so far conducted. For this reason, within the TAILOR trial [12, 13] , we planned an analysis specifically aimed at evaluating KRAS mutational status as a prognostic marker in secondline treatment of advanced NSCLC, and a predictive stratifier for efficacy to erlotinib or docetaxel.
patients and methods study design and patients TAILOR was a not-for-profit multicenter, open label, randomized trial, funded by the Italian Regulatory Agency conducted in 52 Italian hospitals, comparing erlotinib versus docetaxel in second-line NSCLC patients failing front-line platinum-based chemotherapy. Tumor samples were centrally reclassified according to the 2004 WHO classification. Suitable samples were genotyped in parallel by investigators in two independent laboratories using two different techniques. Patients were considered former smokers if they smoked more than 100 cigarettes in their life. All patients who were eligible for participation provided written informed consent with all applicable governing regulations before undergoing any study procedure. Further details can be found in [13] .
procedures Treatment consisted of erlotinib 150 mg given orally every day, or docetaxel given i.v., at either 75 mg/m² every 21 days, or 35 mg/m² on days 1, 8, and 15, every 28 days. At progression, treatment crossing was not permitted. Because of the nature of the interventions, patients were not masked to assigned treatment, but investigators who did tumor genotyping were masked to treatment allocation while investigators who gave treatment and assessed outcomes were masked to KRAS mutational status.
statistical analysis
The trial was initially designed to assess the different effects of docetaxel and erlotinib according to KRAS 12-13 mutation and both EGFR protein expression and amplification, as suggested by the literature in 2007. At the first planned interim analysis, the independent data and safety Monitoring Committee did a preplanned masked efficacy analysis which suggested, in conjunction with other data [14] , that EGFR expression and EGFR amplification were irrelevant. Therefore, the primary objective of the trial became the comparison of efficacy between erlotinib and docetaxel and the sample size was recalculated accordingly. As a result, the power to test the interaction between treatments and KRAS status was greatly reduced and the current analysis was replanned only for exploratory purposes. That notwithstanding, the number of events (187/218 patients) and the mutational rate of 23% observed for KRAS 12-13 in the trial, still allow the detection of a clinical meaningful decrease of at least 39% on both OS and PFS for prognostic effect. The intention-to-treat population was used for all efficacy analyses (N = 218). OS and PFS were assessed from the time of treatment allocation to death from any cause or disease progression. Patients who had not died or had disease progression at the date of study cutoff were censored at the last available information on status. Time-to-event data are described by the Kaplan-Meier curves.
The univariate and multivariate Cox proportional hazards model was used to evaluate KRAS mutational status effect on PFS and OS. The predictive role of KRAS mutational status on treatment was analyzed by means of Cox proportional hazard model and described by forest plots. The BreslowDay test was used to test for interaction between KRAS mutational status and treatment on response. A post hoc review of all the scans of responding patients was done by two independent radiologists, masked to treatment assignment.
All χ 2 tests were calculated for one degree of freedom (unless specified), the associated P values were two sided. The analyses were done with SAS (version 9.2).
results
Among 222 randomized patients (110 to docetaxel and 112 to erlotinib), 218 were fully eligible. Four patients (one in the docetaxel arm and three in the erlotinib arm) were considered ineligible due to the presence of EGFR mutation (N = 1), early death (N = 1), no apparent progression after first-line chemotherapy (N = 1), or not evaluable for KRAS (N = 1 Figure S1 , available at Annals of Oncology online). The baseline characteristics of the randomized patients according to KRAS mutational status are reported in supplementary Table S1 , available at Annals of Oncology online. The mutated KRAS subgroup presents, as expected, a higher percentage of adenocarcinoma histology and smokers compared with wild-type KRAS patients. Remaining characteristics were well balanced between the two groups. KRAS mutational status by isoforms according to histology and smoking habit is reported in supplementary Table S2 , available at Annals of Oncology online. The most frequent isoform was G12C accounting for 43% of all mutations followed by G12D (20%) and G12V (18%). G13 mutation isoforms (G13C and G13D) were seen in 7.9% (N = 4) of all mutated cases and in 9.1% of the smokers patients. At a median follow-up of 33 months (interquartile range 25-33), 211 patients had disease progression or death and 187 died.
prognostic role of KRAS
Survival by KRAS status is reported in Figure 1A . There was no significant difference between the two groups. After accounting for treatment and imbalances in histology types and smoking habits, the hazard ratio (HR) for OS was 1.24 [95% confidence interval (CI) 0.87-1.77, P = 0.232] with median values of 5.7 versus 6.8 months (95% CI 3.8-9.7 and 5.2-8.7), respectively, in the mutated and in the wild-type KRAS group. Within the mutated KRAS group, the four patients harboring G13 mutations tended to have a longer survival (7.3, 13.6, 13.8, and 19.3 months). In Figure 1B are reported the curves for PFS. The multivariate analysis showed a nonsignificant HR for PFS of 1.01 (95% CI 0.71-1.41, P = 0.977). The median PFS was 2.7 months (95% CI 2.4-3.7) in the mutated KRAS group and 2.4 months (95% CI 2.2-2.9) in the wild-type KRAS group. Again, the four patients harboring G13 mutations displayed longer PFS (2.5, 6.9, 7.5, and 12.3 months). Detailed results on univariate and multivariate analyses for OS and PFS are reported in Table 1 . Figure S2A , available at Annals of Oncology online (curves by treatment of KRAS mutated and wild-type patients are reported in supplementary Figure S3 , available at Annals of Oncology online). The PFS analysis also showed a trend favoring docetaxel which was statistically significant in wild-type (HR = 0.68, 95% CI 0.50-0.93, P = 0.016), but not KRAS mutated patients (HR = 0.89, 95% CI 0.51-1.57, P = 0.694). PFS curves by treatment and KRAS mutational status are shown in supplementary Figure S2B , available at Annals of Oncology online (curves by treatment of KRAS mutated and wild-type are reported in supplementary Figure S3 , available at Annals of Oncology online). The relative strength of treatment effects on survival and PFS for the overall population and the two KRAS subgroups, is shown in the forest plot on Figure 2 . The test for interaction was not statistically significant at both the univariate (OSP = 0.992, PFS P = 0.460) and multivariate analysis (OS P = 0.965, PFS P = 0.417), with point estimates clearly favoring the docetaxel arm in all subgroups.
The results obtained by comparing OS and PFS between wild-type KRAS group and the different KRAS mutations 
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Hazard ratio IV, fixed, 95% Cl (G12C, G12D, and G12V) groups are reported in supplementary Figure S4A and B, available at Annals of Oncology online, respectively. RR was 4.5% in the mutated KRAS compared with 10.5% in the wild-type KRAS group. In the mutated KRAS population, 2/20 patients (10%) experienced objective response to docetaxel and none to erlotinib (N = 24). In the wild-type population, 13/ 76 patients (17.1%) achieved objective response with docetaxel compared with 3/76 (3.9%) with erlotinib (supplementary Table S3 , available at Annals of Oncology online). The test for interaction was not significant (P = 0.476).
discussion
TAILOR is the only prospective randomized trial in advanced wild-type EGFR NSCLC patients where the determination of KRAS mutational status was mandatory before randomization to chemotherapy with docetaxel or target therapy with the small molecule erlotinib. Since KRAS discovery in 1982, several retrospective analyses and meta-analyses, involving more than 8000 patients, have been published on the prognostic and predictive values of mutated KRAS in second-line metastatic NSCLC. Two meta-analyses have reported a moderately negative prognostic role for KRAS on survival of NSCLC patients with advanced disease [7, 8] .
In our study, we are unable to confirm mutated KRAS as a negative prognostic marker in advanced NSCLC. Because of limited power, the analysis could have missed a small prognostic effect, which in any case would not be clinically relevant. On the other hand, a more biologically plausible reason for this discrepancy lays in the fact that our study was conducted solely in EGFR wild-type patients. All published analyses suggesting KRAS mutation as a negative prognostic marker, instead, have been conducted in unselected advanced NSCLC populations [4] . In Caucasian patients, the prevalence of EGFR mutation is ∼10%, and mutated EGFR is a known positive prognostic factor [15] . EGFR and KRAS mutations are almost mutually exclusive [3] . In a prognostic analysis focusing on KRAS but conducted in a NSCLC population not genotyped for EGFR, the expected 10% quota of better prognosis patients harboring the EGFR mutation will automatically segregate in the KRAS wild-type subgroup, carrying to the KRAS wild-type status a 'best prognosis burden' in reality ascribable to the EGFR mutation. Indeed, in the Interest trial randomizing gefitinib to docetaxel in unselected NSCLC patients, a subgroup analysis by EGFR mutation status showed a median survival of 15.3 versus 6.2 months for EGFR mutated and wild-type patients, respectively [16] . In our study, the median survival for wild-type patients was 6.8 months.
We have simulated what would have been the impact of including a 10% of EGFR mutated cases in our analysis to establish the prognostic value of KRAS. As a result of this simulation, we have estimated that our median in the 'unselected' wild-type KRAS population (i.e. comprising 90% of EGFR wild-type and 10% of EGFR mutated patients) would have increased the median survival of the wild-type KRAS subgroup from 6.8 to 8.9 months, with a corresponding increase in the HR from 1.32 to 1.45, likely rendering statistically significant, while biologically mistaken, the negative prognostic role of KRAS mutation.
Our analysis also failed to recognize KRAS as significant negative predictor for erlotinib efficacy. Again and interestingly, the only other trial which analyzed the impact of KRAS mutational status within a randomized comparison between an EGFR TKI (gefitinib) and chemotherapy (docetaxel) also failed to find mutated KRAS as a negative predictor of response [17] . In 2007, when TAILOR started, EGFR and KRAS were the only potential biomarkers known for NSCLC. Today, what was once considered the EGFR wild-type 'space', has been populated by a basketful of other mutually exclusive actionable targets, including gene rearrangements in ALK, ROS1, RET, and NTRK1, mutations in HER2 and BRAF, and amplification of MET. All these genotypes account for at least 40% of the previous EGFR wildtype patients [18] . Each of these subpopulations carries its own prognostic significance and while their matching selective inhibitors have been proven active [19] , their specific responsiveness to EGFR TKIs is unknown. Dissecting a true potential predictive role for KRAS in the EGFR wild-type population of TAILOR thus requires extensive genotyping of the non-KRAS mutated subgroup, which is underway. In the meanwhile, and with a pragmatic intent, our results confirm the superiority of docetaxel over erlotinib independently from KRAS, essentially showing an even more favorable trend precisely in the double wild-type subgroup (EGFR and KRAS wild-type). Indeed, docetaxel should have done worse rather than better in this subgroup if KRAS was a strong negative predictor for anti-EGFR inhibition, as in colon cancer [20] . Our findings thus once more support the notion that, in the absence of an identified true target, a 'one fits all' approach is still to be preferable. This strategy is also supported by the results of other recently published trials [21, 22] .
Albeit our results show that KRAS is not a critical prognostic marker or a predictive indicator for tailoring treatments in clinical practice, that is not to say that patients should not be tested for KRAS within the framework of clinical trials or for the purpose of referral. Fortunately, the therapeutic option for wildtype EGFR/KRAS patients is not solely limited to chemotherapy. As already said, due to the plethora of new genetic-driven insights guiding the use of matched targeted agents, a host of new target drugs is already, or will be soon, available for many NSCLC patients with specific genomic determinants [23] . Since these genomic alterations are usually mutually exclusive, the value of testing for KRAS mutational status, in addition to EGFR status, in clinical settings where tumor genotyping at point of care is not yet available on a routine basis, is to identify double wild-type patients for referral to cancer centers with extensive multiplex genotyping programs.
It remains that patients harboring KRAS mutations are ∼20% of NSCLC, pointing to a vast yet unmet clinical need. Currently, there are no KRAS inhibitors in the clinic and targeting KRAS down-stream effectors such as with MEK inhibitors is under extensive investigation [24] . The recent discovery of a selective allosteric inhibitor of G12C mutant KRAS, however, opens the possibility in the future to target at least specific mutant KRAS populations, and is particularly welcomed in NSCLC where the G12C is the most prevalent mutation [25] . In preparation for the clinical development of mutation-specific RAS inhibitors, the biological consequences of the different G12 or G13 substitutions should be dissected. Although the number of patients in our study did not allow to infer on the prognostic or predictive 
